यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelin hydrokloridi - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboottiset aineet - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - aivolisäkkeen ja hypotalamuksen hormonit ja analogit - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

vital pharma nordic aps - deflazacort - tabletti - 30 mg - deflatsakorti

फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

vital pharma nordic aps - deflazacort - tabletti - 6 mg - deflatsakorti

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

mylan s.a.s. - pregabaliini - anxiety disorders; neuralgia; epilepsy - epilepsialääkkeet, - epilepsypregabalin mylan pharma on liitännäishoitona aikuisilla, joilla on paikallisalkuisia kohtauksia toissijaisesti yleistyvä tai yleistymätön kohtaus. yleistynyt ahdistuneisuus disorderpregabalin mylan pharma on tarkoitettu hoitoon yleistynyt ahdistuneisuushäiriö (gad) aikuisilla.

फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

bayer ag -

यूरोपीय संघ - फ़िनिश - EMA (European Medicines Agency)

acino pharma gmbh - klopidogreeli - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - klopidogreeli on tarkoitettu aikuisten atherothrombotic tapahtumien ehkäisemiseksi: * sydäninfarkti (muutamasta vasta alle 35 vrk) kärsivien potilaiden iskeeminen aivohalvaus (alkaen 7 päivää kunnes alle 6 kuukautta) tai perustettu reuna valtimosairaus. lisätietoja, katso kohta 5.

फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

ace pharmaceuticals bv - hydrocortisone - tabletti, kalvopäällysteinen - 10 mg / 5 mg - hydrokortisoni

फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

ace pharmaceuticals bv - hydrocortisone - tabletti, kalvopäällysteinen - 10 mg - hydrokortisoni

फ़िनलैंड - फ़िनिश - Fimea (Suomen lääkevirasto)

ace pharmaceuticals bv - hydrocortisone - tabletti, kalvopäällysteinen - 5 mg - hydrokortisoni